Project Echo: Tele-mentoring to manage immune-related adverse events in patients receiving cancer immunotherapies: Endocrine Toxicities with Immune Checkpoint Inhibitors - November 15, 2022

This page is for learners who attended the November 15, 2022, virtual session to claim credit.

Claiming Credit

Thank you for participating in this program. Once logged in, please click on "Take Course" on the right-hand side and your enrollment will be recorded. You will be prompted to complete the posttest, evaluation and claim your credit on the following page.
 
 
Immunotherapies have yielded impressive clinical benefits in a growing number of cancers, and in many cases, they have surpassed the efficacy of existing therapies. Immunotherapy usage is expected to increase in cancer care with the rapid approval of several new drugs and expanded indications for existing drugs in this class. However, the expanding armamentarium of immunotherapies available to treat patients with cancer poses a challenge to community clinicians with respect to integrating this new class of agents into practice. Community cancer programs need guidance regard the practical issues that cancer programs must navigate to provide immunotherapy safely and effectively in their own communities.

Target Audience

The target audience for this initiative includes oncologists, oncology advanced practice providers (nurse practitioners, physician assistants), oncology pharmacists, oncology nurses, and other healthcare professionals (HCPs) involved in treating patients with cancer immunotherapies.

Learning Objectives

   At the end of this educational activity, participants will be able to: 
  • Apply evidence-based practices for the monitoring and management of irAEs in patients receiving cancer immunotherapies         
  • Improve coordination and communication with non-oncology specialists and with patients/caregivers to manage irAEs in patients receiving cancer immunotherapies
  • Review strategies for providing equitable care for underserved patients receiving cancer immunotherapies

Additional Information

AttachmentSize
PDF icon BU_ProjectEchoCE_Statement.pdf168.71 KB
Course summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit™
    Boston University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. Boston University School of Medicine designates this Enduring activity for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  • 1.00 ANCC
    Boston University School of Medicine Continuing Nursing Education is accredited with distinction as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.
  • 1.00 Participation
Course opens: 
11/15/2022
Course expires: 
11/14/2023
Rating: 
0
Physicians: This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Boston University School of Medicine and the Association of Community Cancer Centers.
 
Boston University School of Medicine designates this live activity for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
 
Nurses: Boston University School of Medicine Continuing Nursing Education is accredited with distinction as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.
 
This educational activity has been provided by Boston University School of Medicine Continuing Nursing Education and jointly provided by the Association of Community Cancer Centers.
 
Contact Hours: 1.00, of which 1 is pharmacology credit worthy
 

The University of Rhode Island College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.  This is an application-based educational activity. Pharmacists will receive 1.0 contact hour (0.10 CEUS) for the educational activity. No partial credit is available. 

UNIVERSAL ACTIVITY NUMBERS (UAN) 0060-9999-22-085-L01-P

Please see the additional information tab in the Overview section for directions on how to claim credit.

Available Credit

  • 1.00 AMA PRA Category 1 Credit™
    Boston University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. Boston University School of Medicine designates this Enduring activity for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  • 1.00 ANCC
    Boston University School of Medicine Continuing Nursing Education is accredited with distinction as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.
  • 1.00 Participation

The activity has been provided by an educational grant from BMS.

Please login or register to take this course.

Please click on "Take Course" above to begin the credit claiming process.